DORMANT studio
localhost:3000

Opportunity radar

4,186,134 patents indexed · 165,974,948 citations · issued 2005-01-04 → 2026-05-05

Showing50 of 30,058
Free-text
CPC starts with (comma sep)
Min fwd citations
Clear
Patent #TitleAssetsIssuedExpiresFwd citesScore
12552810Crystalline forms of CFTR modulators🖼🧊📄§2026-02-172041-08-12031
12551480Treatment using EYP001🖼🧊📄§2026-02-172040-07-17031
12551529Liquid formulation of a VEGF antagonist🖼🧊📄§2026-02-172043-02-23031
12551517Probiotics for cognitive and mental health🖼🧊📄§2026-02-172042-09-30031
12551521Compositions including pine bark extract, berryfruit extract and a source of l-theanine and uses thereof🖼🧊📄§2026-02-172038-11-13031
12551468Pharmaceutical composition for oral administration, for treatment of liver cancer🖼🧊📄§2026-02-172040-11-25031
12551548HIV vaccine compositions, methods, and uses thereof🖼🧊📄§2026-02-172041-06-10031
12551551Compositions comprising α-factor prepro sequence and uses thereof🖼🧊📄§2026-02-172043-01-05031
12552834Selective MENA binding peptides🖼🧊📄§2026-02-172042-01-25031
12551553Methods for manufacturing an adjuvant🖼🧊📄§2026-02-172039-11-27031
12551734Betacoronavirus mRNA vaccines🖼🧊📄§2026-02-172044-12-23031
12551484Methods of treatment and/or prevention of major adverse cardiovascular events (MACE) with a combination of a BET bromodomain inhibitor and a sodium dependent glucose transport 2 inhibitor🖼🧊📄§2026-02-172040-11-04031
12553063CAS13 family AAV vectors and uses thereof🖼🧊📄§2026-02-172040-04-10031
12552849Method of reducing bispecific t cell engager or chimeric antigen receptor t cell mediated cytokine release syndrome using interleukins-4, -10, or a fusion protein thereof🖼🧊📄§2026-02-172044-09-09031
12551523HIF-1 activator🖼🧊📄§2026-02-172042-10-04031
12553041Formulations and doses of pegylated uricase🖼🧊📄§2026-02-172040-06-04031
12551522Herbal compositions and methods for treating and preventing SARS-CoV-2 virus infection🖼🧊📄§2026-02-172042-11-09031
12552874Antibodies to carbohydrate antigens🖼🧊📄§2026-02-172040-11-25031
12551543Vaccine compositions comprising C—C motif chemokine 22 (CCL22) or fragments thereof🖼🧊📄§2026-02-172042-03-10031
12551475Methods and compositions for treating RNA viral infections🖼🧊📄§2026-02-172041-06-01031
12552824C-mannoside compounds useful for the treatment of urinary tract infections🖼🧊📄§2026-02-172043-04-28031
12551518Probiotic system and use thereof🖼🧊📄§2026-02-172040-12-11031
12551499Highly active compounds against COVID-19🖼🧊📄§2026-02-172043-09-15031
12551495Phytoecdysones and derivatives thereof for use in treating disordered respiratory function on viral infection🖼🧊📄§2026-02-172041-03-24031
12551564IRAK degraders and uses thereof🖼🧊📄§2026-02-172040-12-09031
12551494Pharmaceutical composition for preventing or treating dengue fever🖼🧊📄§2026-02-172042-02-17031
12551569RNAi agents for inhibiting expression of microtubule associated protein tau (MAPT), compositions thereof, and methods of use🖼🧊📄§2026-02-172045-03-30031
12552793Purine derivative and medical use thereof🖼🧊📄§2026-02-172040-12-30031
12552733Terpenophenolic compounds and their use🖼🧊📄§2026-02-172041-03-31031
12551514Combination of non-viable cells of Streptococcus pyogenes and immune checkpoint inhibitor for the treatment of triple negative breast cancer and non-muscle invasive bladder cancer🖼🧊📄§2026-02-172045-07-25031
12552754Leflutrozole compositions of matter and processes for preparation🖼🧊📄§2026-02-172045-07-23031
12551493Composition for enhancing therapeutic effect of stem cell, comprising immunosuppressant, and method for enhancing therapeutic effect of stem cell using same🖼🧊📄§2026-02-172040-10-21031
12552736Compositions for preventing and/or treating degenerative disorders of the central nervous system and/or lysosomal storage disorders🖼🧊📄§2026-02-172042-06-13031
12553027Generation and cryopreservation of pluripotent stem cell-derived clinical grade corneal endothelial cells🖼🧊📄§2026-02-172039-12-12031
12551506Differentiation of olfactory mucosa derived mesenchymal stem cells to schwann cells for peripheral nerve repair🖼🧊📄§2026-02-172042-04-25031
12551457Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics🖼🧊📄§2026-02-172043-05-01031
12552873Anti-PSGL-1 compositions and methods for modulating myeloid cell inflammatory phenotypes and uses thereof🖼🧊📄§2026-02-172040-06-02031
12551555Compositions and methods for potentiating immune activity🖼🧊📄§2026-02-172042-06-10031
12552788IMDQ-PEG-CHOL adjuvant and uses thereof🖼🧊📄§2026-02-172041-10-07031
12551488Pharmaceutical compositions comprising meloxicam🖼🧊📄§2026-02-172045-05-15031
125527891H-pyrrolo[2,3-c]pyridine compounds and application thereof🖼🧊📄§2026-02-172041-09-24031
12552795Pyrrolotriazine derivatives for treating kit-and PDGFRA-mediated diseases🖼🧊📄§2026-02-172040-04-08031
12551541Albumin bound macromolecule tri-agonist activating GLP 1/GIP/glucagon receptors and methods therefor🖼🧊📄§2026-02-172044-06-25031
12552875Anti-human Cripto-1 antibody🖼🧊📄§2026-02-172040-11-10031
12552807PCSK9 inhibitors and methods of use thereof🖼🧊📄§2026-02-172041-12-20031
12551489Pharmaceutical compositions comprising meloxicam🖼🧊📄§2026-02-172045-05-29031
12552760Compounds for increasing the nicotinamide adenine dinucleotide in a subject and methods of use thereof🖼🧊📄§2026-02-172043-04-21031
12552871Nucleic acids encoding humanized anti-NGF antibodies🖼🧊📄§2026-02-172041-03-12031
12551458Topical pharmaceutical composition containing phospholipids🖼🧊📄§2026-02-172044-10-28031
12551558Compositions and methods for promoting hematopoietic cell cytotoxicity🖼🧊📄§2026-02-172040-04-12031